GHRP-2

What Is GHRP-2?

GHRP-2, formally known as pralmorelin, is a synthetically produced peptide that activates growth hormone secretion through ghrelin receptor binding. As the first compound developed in the growth hormone secretagogue class, it has contributed substantially to hormonal research. GHRP-2 has been evaluated in stage II clinical research for growth-related conditions and continues to be studied for its effects on appetite, muscle metabolism, immune regulation, and sleep patterns. The peptide displays oral and sublingual bioactivity in controlled research settings.

GHRP-2 Structure

The peptide structure of GHRP-2 is designed to ensure receptor selectivity and biological durability. This configuration supports effective engagement with growth hormone signaling pathways during experimental use.

GHRP-2 Effects

1. Lean Muscle Maintenance

Research in animal models indicates that GHRP-2 supports lean muscle mass by promoting protein synthesis and inhibiting protein breakdown. Reduced activity of atrogin-1 and MuRF1 limits catabolic processes, while growth hormone and insulin-like growth factor-1 signaling enhances anabolic balance.

2. Appetite Stimulation

GHRP-2 administration has been associated with increased food intake. Appetite enhancement has been investigated in research settings involving nutritional insufficiency, where caloric intake plays a critical role in recovery and metabolic stability.

3. Cardiac Cellular Protection

Studies involving cardiac cells suggest that GHRP-2 reduces apoptosis during metabolic stress. These cardioprotective effects are believed to involve mitochondrial stabilization and peptide-specific receptor interactions.

4. Immune System Activation

GHRP-2 has demonstrated stimulatory effects on the thymus, supporting T-cell maturation and immune diversity. This activity is relevant to studies of immune decline associated with aging.

5. Sleep Quality Improvement

Experimental findings indicate that GHRP-2 increases deep sleep duration while altering REM sleep proportions. These effects are linked to improved sleep quality, cognitive function, and physiological recovery.

6. Pain Signaling Interaction

GHRP-2 has shown antinociceptive effects in animal models through selective opioid receptor engagement. This specificity differentiates it from traditional opioid compounds with broader systemic effects.

Research Use Disclaimer

Animal research indicates favorable tolerability and bioavailability; however, these findings cannot be applied to humans. GHRP-2 is intended solely for scientific research and educational use and is not approved for human consumption.

Scientific Attribution

This document acknowledges peer-reviewed research and credits the scientific contributions of Dr. Logan, M.D., and Dr. Jean-Alain Fehrentz. References are provided strictly for scholarly recognition and do not imply endorsement or commercial relationship.

Referenced Citations

1. R. Hu et al., "Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation," PloS One, vol. 11, no. 2, p. e0149461, 2016.
2. D. Yamamoto et al., "GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1," Life Sci., vol. 82, no. 9–10, pp. 460–466, Feb. 2008.
3. L. T. Phung et al., "The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine," Domest. Anim. Endocrinol., vol. 18, no. 3, pp. 279–291, Apr. 2000.
4. B. Laferrère, C. Abraham, C. D. Russell, and C. Y. Bowers, "Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men," J. Clin. Endocrinol. Metab., vol. 90, no. 2, pp. 611–614, Feb. 2005.
5. B. Laferrère, A. B. Hart, and C. Y. Bowers, "Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake," Obes. Silver Spring Md, vol. 14, no. 6, pp. 1056–1063, Jun. 2006.
6. G. Muccioli et al., "Growth hormone-releasing peptides and the cardiovascular system," Ann. Endocrinol., vol. 61, no. 1, pp. 27–31, Feb. 2000.
7. V. Bodart et al., "Identification and characterization of a new growth hormone-releasing peptide receptor in the heart," Circ. Res., vol. 85, no. 9, pp. 796–802, Oct. 1999.
8. D. D. Taub, W. J. Murphy, and D. L. Longo, "Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways," Curr. Opin. Pharmacol., vol. 10, no. 4, pp. 408–424, Aug. 2010.
9. G. Gopinadh et al., "Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man," Neuroendocrinology, vol. 66, no. 4, pp. 278–286, Oct. 1997.
10. P. Zeng et al., "Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice," Peptides, vol. 55, pp. 103–109, May 2014.
11. Moulin, A. , Ryan, J. , Martinez, J. and Fehrentz, J. (2007), Recent Developments in Ghrelin Receptor Ligands. ChemMedChem, 2: 1242-1259.